Avrobio receives FDA rare pediatric disease status for cystinosis therapy
Pharmaceutical Technology
SEPTEMBER 22, 2022
Avrobio has received rare pediatric disease designation from the US Food and Drug Administration (FDA) for its investigational gene therapy, AVR-RD-04, designed to treat cystinosis. AVR-RD-04 works by genetically modify a patient's hematopoietic stem cells (HSCs) to express the gene that encodes the cystinosin protein.
59 
Let's personalize your content